叶正良,天津天士力之骄药业有限公司董事长兼总经理

Ye Zhengliang

He is appointed as the Chairman & General Manager of Tianjin Tasly Pride Pharmaceutical Co., Ltd., as well as the Project Director of the FDA-CMC Project of Tianjin Tasly Group Co., Ltd. with a Doctor Degree in Zhejiang University Pharmaceutical Analysis. He used to be the Director of Tianjin Tasly Group Co., Ltd. Traditional Chinese Medicine Research Institute and the Director of Tianjin Tasly Group Co., Ltd. Institute since 1995 employed by Tianjin Tasly Group Co., Ltd., in charge of new drug development, TCM modernization & globalization research, TCM quality system technical research, TCM patent research etc. He has been the Chairman & General Manager of Tianjin Tasly Pride Pharmaceutical Co., Ltd. ever since 2005, directing TCM injection R&D strategy management, product industrialization and product management and so on. He took the position of the Project Director of Tasly International Industrialization Project (also known as FDA-CMC Project) in October 2010 to supervise the Dantonic® international industrialization and specification establishment.

He has been devoted in medicine field for 23 years, creatively accomplish TCM quality system technical research, TCM industrialization key technology study and solve TCM modernization & globalization decisive technical problems. Meanwhile he hosts numerous innovative projects and several National Key Technologies R&D Programs as well as Tianjin R&D Projects, winning ten-odd Provincial/Ministerial and above Science & Technology Awards.